AR128801A1 - Combinación de oligonucleótidos dirigidos a stat3 e inhibidores de pd-l1 - Google Patents

Combinación de oligonucleótidos dirigidos a stat3 e inhibidores de pd-l1

Info

Publication number
AR128801A1
AR128801A1 ARP230100647A ARP230100647A AR128801A1 AR 128801 A1 AR128801 A1 AR 128801A1 AR P230100647 A ARP230100647 A AR P230100647A AR P230100647 A ARP230100647 A AR P230100647A AR 128801 A1 AR128801 A1 AR 128801A1
Authority
AR
Argentina
Prior art keywords
stat3
targetting
oligonucleotides
inhibitors
combination
Prior art date
Application number
ARP230100647A
Other languages
English (en)
Inventor
Marc Abrams
Shanthi Ganesh
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of AR128801A1 publication Critical patent/AR128801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método para tratar el cáncer en un sujeto que ha recibido o está recibiendo un inhibidor de PD–L1, en donde el método comprende administrar un oligonucleótido de ARNi que comprende una cadena antisentido de 15 a 30 nucleótidos de longitud y una cadena con sentido de 15 a 40 nucleótidos de longitud, en donde las cadenas antisentido y con sentido forman una región dúplex, en donde la cadena antisentido comprende una región de complementariedad con una secuencia diana de ARNm STAT3 y en donde la región de complementariedad tiene al menos 15 nucleótidos contiguos de longitud, tratando así el cáncer en el sujeto.
ARP230100647A 2022-03-15 2023-03-15 Combinación de oligonucleótidos dirigidos a stat3 e inhibidores de pd-l1 AR128801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263320163P 2022-03-15 2022-03-15

Publications (1)

Publication Number Publication Date
AR128801A1 true AR128801A1 (es) 2024-06-12

Family

ID=88024405

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100647A AR128801A1 (es) 2022-03-15 2023-03-15 Combinación de oligonucleótidos dirigidos a stat3 e inhibidores de pd-l1

Country Status (3)

Country Link
AR (1) AR128801A1 (es)
TW (1) TW202406558A (es)
WO (1) WO2023178141A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117890603A (zh) * 2024-01-17 2024-04-16 南通大学附属医院 Pd-l1作为药物靶点在筛选抑制肌腱粘连药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196781A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
HUE043227T2 (hu) * 2014-10-24 2019-08-28 Astrazeneca Ab Kombináció

Also Published As

Publication number Publication date
TW202406558A (zh) 2024-02-16
WO2023178141A3 (en) 2023-10-19
WO2023178141A2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
AR128801A1 (es) Combinación de oligonucleótidos dirigidos a stat3 e inhibidores de pd-l1
CO2020001354A2 (es) Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia un arni, por ejemplo, un ácido ribonucleico de hebra doble (arnhd), composiciones dirigidas al gen serpinc1 y métodos para usar dicho arni, por ejemplo, arnhd, composiciones para tratar un evento de sangrado en un sujeto que tiene una hemofilia (por ejemplo, con o sin inhibidores).
PE20230993A1 (es) Construcciones de iarn y metodos para inhibir la expresion de marc1
ES2633565T3 (es) ARN no codificantes asociados a polycomb
BR112015022876A2 (pt) agente, composição farmacêutica e método para inibição da expressão do componente do complemento c5, uso do referido agente, vetor e célula.
CL2021001552A1 (es) Moléculas inhibidoras de ácido nucleico de doble hebra que contienen un triloop
AR090641A1 (es) Composiciones y metodos para inhibir la expresion del gen alas1
Liang et al. Small nucleolar RNA interference induced by antisense or double-stranded RNA in trypanosomatids
MX2020002872A (es) Moléculas de arn.
Srikantan et al. Paradoxical microRNAs: individual gene repressors, global translation enhancers
CL2021002842A1 (es) Moléculas inhibidoras de ácido nucleico bicatenario con cadenas de sentido acortadas
Zhang et al. Epigenetic mechanisms underlying the aberrant catabolic and anabolic activities of osteoarthritic chondrocytes
AR123420A1 (es) Inhibidores de dux4 y métodos de uso de estos
MX2020010802A (es) Moleculas inhibidoras de acidos nucleicos de caracter bicatenario modificadas con nucleotidos que aumentan la tm.
Stierlé et al. Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs
AR083445A1 (es) siARN CONTRA LA FIBROSIS
AR123152A1 (es) Composiciones y métodos para inhibir la expresión de plp1
CN101173275B (zh) 抑制sars冠状病毒m蛋白基因表达的小干扰rna及其编码基因与应用
AR125230A1 (es) COMPOSICIONES DE AGENTES DE ARNi CONTRA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
AR125332A1 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
AR112270A1 (es) Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia
AR121655A1 (es) COMPOSICIONES DE ARNi CONTRA CORONAVIRUS Y MÉTODOS DE USO DE LAS MISMAS
US20200397813A1 (en) Cancer therapeutic targeting using mutant p53-specific sirnas
AR125019A1 (es) COMPOSICIONES DE ARNi CONTRA CETOHEXOQUINASA (KHK) Y SUS MÉTODOS DE USO
AR125021A1 (es) COMPOSICIONES DE ARNi CONTRA EL GEN SIMILAR A ANGIOPOYETINA 3 (ANGPTL3) Y SUS MÉTODOS DE USO